Effectiveness of Divalproex Sodium (Depakote) in Treating Children With Temper Outbursts and Severe Mood Swings
Information source: National Institute on Drug Abuse (NIDA)
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Mood Disorders
Intervention: Divalproex Sodium (Depakote) (Drug)
Phase: Phase 2
Status: Completed
Sponsored by: National Institute on Drug Abuse (NIDA) Official(s) and/or principal investigator(s):
Stephen Donovan, MD, Principal Investigator, Affiliation: Columbia University
Summary
The purpose of this study is to determine the effectiveness of divalproex sodium (Depakote)
versus placebo in treating children with temper outbursts and severe mood disorders.
Clinical Details
Official title: Double-Blind, Placebo-Controlled Study of Depakote (Divalproex Sodium) in Children With Temper Outbursts and Severe Mood Swings
Study design: Treatment, Randomized, Double-Blind, Placebo Control, Crossover Assignment, Safety/Efficacy Study
Primary outcome: Reduction in symptoms of explosive mood disorder; measured throughout the study and at Week 12
Detailed description:
Depakote has been used to treat seizures in children for more than 20 years. The purpose of
this study is to determine the effectiveness of divalproex sodium (Depakote) in treating
children with temper outbursts and severe mood disorders.
This study will last 12 weeks. Participants will be randomly assigned to receive either 250
mg Depakote or placebo. The dose of medication will increase at the end of Week 1 to 500 mg
of either depakote or placebo; participants will remain on this dose through Week 5. At Week
6, participants will cross-over and receive the other treatment (either depakote or placebo),
which they will take through Week 12. Study visits will occur weekly and will include a
physical exam, blood and urine tests, and self-reports of adverse events. In addition,
caregivers will complete reports about mood swings throughout the study.
Eligibility
Minimum age: 7 Years.
Maximum age: 11 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Meets criteria for Explosive Mood Disorder (EMD)
- Explosive temper as evidenced by four or more outbursts of rage, property destruction,
or fighting per month
- Mood liability as evidenced by multiple, daily, distinct shifts from normal to
irritable mood with withdrawn or boisterous behavior, occurring without a clear
precipitant
- History of an EMD for one year without treatment
- EMD symptoms resulting in impairment in two or more of the following areas: school,
the law, family, substance use, peers, or work
- EMD symptoms do not occur only during substance toxicity or withdrawal
- EMD symptoms are not confined to a single setting or context
- Parent and child willing to consent to study
- Inadequate response to an adequate trial (8 weeks) of psychotherapy and/or family
therapy
Exclusion Criteria:
- Meets criteria for pervasive developmental disorder or childhood schizophrenia
- Seizure or other neurologic disturbance
- Pregnant
- Moderate to severe mental retardation
- Physical exam or laboratory results with significant abnormalities
- Positive Hepatitis screen test
- Liver dysfunction
- Active suicidal or homicidal ideation
- History of suicide attempts
- History of barbiturate use
- Unequivocal manic or hypomanic episode
- Meets criteria for attention deficit hyperactivity disorder (ADHD) and has not failed
a trial of psychostimulants for ADHD
- Meets criteria for major depression in prepuberty
- If female, unwilling to use an effective method of contraception for the duration of
the study
- Mitochondrial disease or family history of mitochondrial disease
Locations and Contacts
New York State Psychiatric Institute, New York, New York 10032, United States
Additional Information
Starting date: September 2000
Ending date: August 2005
Last updated: April 27, 2006
|
